V. Vdovin

发表

octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment

J. Oldenburg, A. Klukowska, V. Komrska, 2020, Therapeutic advances in hematology.

Long‐term tolerability, immunogenicity and efficacy of Nuwiq® (human‐cl rhFVIII) in children with severe haemophilia A

R. Liesner, A. Klukowska, V. Vdovin, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Novel, human cell line‐derived recombinant factor VIII (Human‐cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics

R. Liesner, A. Klukowska, V. Vdovin, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study

V. Jiménez‐Yuste, A. Pavlova, V. Vdovin, 2022, TH open : companion journal to thrombosis and haemostasis.

The use of recombinant–activated factor VII in von Willebrand disease: a case series

J. Blatny, P. Smejkal, V. Vdovin, 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Efficacy and safety of OCTANINE F in children with haemophilia B

A. Klukowska, V. Vdovin, P. Laguna, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study

E. Neufeld, J. Oldenburg, V. Jiménez‐Yuste, 2021, Thrombosis and Haemostasis.

Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

E. Neufeld, T. Lambert, M. Carcao, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

J. Oldenburg, V. Jiménez‐Yuste, A. Pavlova, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate®: Final report from a prospective study

A. Pavlova, A. Klukowska, V. Komrska, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics

E. Santagostino, M. Ozelo, V. Vdovin, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy, Immunogenicity, Pharmacokinetics, and Safety Of Human-cl rhFVIII – a GCP Study In Children With Severe Haemophilia A

A. Klukowska, V. Vdovin, T. Szczepański, 2013 .

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate® in the Observational ObsITI Study,

C. Escuriola-Ettingshausen, V. Vdovin, N. Zozulya, 2011 .

Features of infusions and tranfusions within the complex treatment in patients with multisystem trauma

V. Vdovin, R. A. Ibragimov, F. Galyautdinov, 2015 .